SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

17 Nov 2023 Evaluate

Lupin has informed that it enclosed a Press release regarding receipt of US FDA approval for the Company’s Abbreviated New Drug Application for Ganirelix Acetate Injection, 250 mcg/0.5 mL Single-Dose Prefilled Syringe, to market a generic equivalent to the reference listed drug of Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. 

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2420.15 12.70 (0.53%)
30-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1862.70
Dr. Reddys Labs. 1356.85
Cipla 1465.15
Zydus Lifesciences 1112.20
Lupin 2420.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: